Mars has been granted a patent for a method of diagnosing and treating chronic kidney disease (CKD) in animals. The method involves determining the amount of magnesium in a blood sample and comparing it to reference values. If the magnesium levels are below or above certain predetermined values, the animal is diagnosed as being at risk for CKD and provided with a treatment regimen that may include magnesium administration or other therapies. GlobalData’s report on Mars gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Mars, filled confectionary manufacturing was a key innovation area identified from patents. Mars's grant share as of September 2023 was 55%. Grant share is based on the ratio of number of grants to total number of patents.
Diagnosing and treating chronic kidney disease in animals using magnesium
A recently granted patent (Publication Number: US11771113B2) describes a method for diagnosing and treating animals at risk for chronic kidney disease (CKD). The method involves obtaining a blood sample from the animal and determining the amount of magnesium in the sample. This amount is then compared to predetermined reference values based on average magnesium levels in a control population. If the amount of magnesium is below a first predetermined value or above a second predetermined value, the animal is diagnosed as being at risk for CKD. In such cases, the animal is provided with a treatment regimen that may include administering a composition with magnesium or a salt thereof, reducing phosphate and protein intake, administering polyunsaturated fatty acids, and other therapies.
The patent also includes the step of determining the amount of FGF23 (a biomarker) in the blood sample and comparing it to a third predetermined reference value. A higher FGF23 level compared to the second predetermined reference value indicates a higher likelihood of effective treatment. Additionally, the method involves determining the amount of other biomarkers such as phosphate, creatinine, blood urine nitrogen (BUN), and parathyroid hormone (PTH) in the blood sample. If these biomarkers are above a fourth predetermined reference value, it indicates a higher likelihood of effective treatment.
The treatment regimen mentioned in the patent includes various options such as dietary therapy, hemodialysis, renal replacement therapy, withdrawal of kidney damaging compounds, kidney transplantation, and modifying diuretic administration. The patent also suggests determining the blood pressure of the animal and administering a prevention or treatment regimen for hypertension if the blood pressure is higher than a fifth predetermined reference value.
The method described in the patent can be applied to companion animals such as dogs and cats. The treatment regimen may involve administering a composition with magnesium or a salt thereof, with the amount of magnesium ranging from about 50 mg/1000 Kcal to about 500 mg/1000 Kcal. The composition can be provided to the animal at least once a day.
Overall, this patent provides a method for diagnosing and treating animals at risk for chronic kidney disease, offering a range of treatment options based on biomarker levels in the blood sample. The method aims to improve the effectiveness of treatment and potentially prevent the progression of CKD in animals.
To know more about GlobalData’s detailed insights on Mars, buy the report here.